- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01493089
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
August 12, 2013 updated by: Norgine
A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy
Heartburn is the main symptom of Gastroesophageal Reflux Disease (GERD), which, accompanied by acid regurgitation and other symptoms, has a substantial negative impact on a patients' quality of life.
Although a number of treatment options are available, a more effective therapy is still required.
The failure of proton pump inhibitors (PPIs) to completely resolve symptoms is an accepted problem, with approximately 25% of patients with GERD continuing to experience the symptoms of heartburn in spite of treatment.
This study aims to demonstrate an earlier onset to relief of symptoms in patients suffering from heartburn associated with GERD using an immediate-release omeprazole/sodium bicarbonate formulation when compared with delayed-release omeprazole (Losec®).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
239
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Warsaw, Poland, 02-781
- Department of Gastroenterology and Hepatology, Oncology Centre, Roentgena
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Study patients will be included in the study if they satisfy the following criteria:
- Male or female, between 18 and 75 years old.
- History of frequent episodes of heartburn associated with GERD for at least 2 3 days per week during 2-4 weeks before screening and have responded to standard PPI therapy in the past 12 months.
- Have not taken on-demand PPI therapy for > 3 consecutive days within 4 weeks before the screening period.
- The patient's written informed consent must be obtained prior to inclusion.
- Willing and able to complete the entire procedure and to comply with study instructions.
- Females of childbearing potential must employ an adequate method of birth control.
Inclusion criteria applicable to Screening period:
- Recorded at least 1 evaluable episode of heartburn on 2 separate days at level 4 or higher on the 9-point Likert severity scale (point 3 on a 0-8 point scale) prior to randomisation.
- Competent in the use and completion of the e-diary.
Exclusion Criteria:
Study patients will be excluded if they meet any of the following criteria:
- Age < 18 or > 75 years old.
- Intake of any medication for the purpose of the eradication of Helicobacter pylori (H. pylori) during the last 28 days before the start of the study.
- Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (≥ 3 consecutive days per week) during the last 28 days before the start of the study; except regular intake of enteric coated aspirin dosages up to 150 mg/d.
- Previously underwent acid-lowering surgery or other surgery of the oesophagus and/or upper gastrointestinal tract (excluding: appendectomy, cholecystectomy and polypectomy).
- History of co-existing disease that affects the oesophagus (e.g. Barrett's oesophagus, Zollinger-Ellison syndrome, oesophageal stricture), and have undergone an endoscopy with results of incomplete healing of erosions following standard PPI therapy within the last 3 months.
- History of active gastric or duodenal ulcers within 3 months of the first dose of the study drug or had acute upper gastrointestinal (GI) bleeding within last 6 months.
- Documented presence of severe renal or hepatic insufficiency.
- Known hypersensitivity to omeprazole.
- Concurrent participation in a study with an investigational drug or participation within 30 days of study entry.
- Females who are pregnant, or planning a pregnancy. Females of child bearing potential not using reliable methods of birth control.
- Clinically significant laboratory abnormality or disease which, in the opinion of the Investigator, will create a risk for the patient, obscure the effects of study treatment or interfere with study results.
- Received or require any of the following drugs within 2 weeks before the first dose of study or continue to need these drugs for concurrent therapy: theophylline, bismuth salts, warfarin, phenytoin, tacrolimus, diazepam, cyclosporine, disulfiram, benzodiazepines, barbiturates, antineoplastic agents, erythromycin, clarithromycin, sucralfate, clopidogrel or protease inhibitors.
- Taking concomitant medications that rely on the presence of gastric acid for optimal bioavailability (e.g. ketoconazole, ampicillin esters or iron salts).
- Onset of psychoactive medication (e.g. depressants, stimulants or hallucinogens) in the previous 6 months and during the entire course of the study.
Exclusion criteria applicable to Screening period:
- Recorded < 1 episode of heartburn on 2 separate days at level 4 on the 9 point Likert severity scale (point 3 on a 0-8 point scale) during the 7 day screening period prior to randomisation
- Completing < 90% (< 9 out of 10) of the time points with evaluable data on the e diary.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zegerid
Treatment of heartburn with Zegerid
|
20 mg Zegerid suspension to be taken when heartburn occurs.
Maximum one dose per day on 3 out of 14 days.
|
Active Comparator: Losec
Treatment of heartburn with Losec
|
20 mg Losec capsule to be taken when heartburn occurs.
Maximum one dose per day on 3 out of 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient
Time Frame: up to 14 days following treatment
|
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more
|
up to 14 days following treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Time to Sustained Partial Response
Time Frame: up to 14 days
|
Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more
|
up to 14 days
|
Median Time to Sustained Total Relief
Time Frame: 14 days
|
Time to sustained total relief, defined as zero severity (no heartburn) on a 9-point Likert severity scale, which is sustained for 45 minutes or more
|
14 days
|
Percentage of Patients Responding in 45 Minutes
Time Frame: up to 14 days
|
percentage of patients who have achieved sustained partial response, sustained response, or sustained total relief, by 45 minutes
|
up to 14 days
|
Percentage of Patients Responding in 60 Minutes
Time Frame: 14 days
|
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 60 minutes
|
14 days
|
Percentage of Patients Responding in 90 Minutes
Time Frame: 14 days
|
Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 90 minutes
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: J Regula, MD, Dept of Gastroenterology and Hepatology, Roentgena, Warsaw, Poland
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
December 13, 2011
First Submitted That Met QC Criteria
December 14, 2011
First Posted (Estimate)
December 15, 2011
Study Record Updates
Last Update Posted (Estimate)
August 13, 2013
Last Update Submitted That Met QC Criteria
August 12, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophagitis
- Peptic Ulcer
- Duodenal Diseases
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Heartburn
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Proton Pump Inhibitors
- Omeprazole, sodium bicarbonate drug combination
Other Study ID Numbers
- ZEG-01/2010 (GERD)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Scandinavia PharmaRecruitingGastroesophageal Reflux DiseaseColombia
-
King Chulalongkorn Memorial HospitalCompleted
Clinical Trials on Zegerid
-
NorgineCompletedAcid Reflux | Gastro Oesophageal Reflux DiseaseUnited Kingdom
-
Yvonne RomeroBausch Health Americas, Inc.CompletedErosive EsophagitisUnited States
-
Procter and GambleCompletedNormal Healthy Subject PopulationUnited States
-
BayerCompleted
-
BayerCompleted
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
BayerCompleted
-
Stanford UniversityTerminatedGastroesophageal Reflux | Barrett EsophagusUnited States
-
University of Missouri-ColumbiaCompleted